Journal of the American Society of Nephrology
2009 JASN IMPACT FACTOR 7.689 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on January 21, 2010
J Am Soc Nephrol 21: 468-477, 2010
© 2010 American Society of Nephrology
doi: 10.1681/ASN.2009060658

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2009060658v1
21/3/468    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oppermann, M.
Right arrow Articles by Castrop, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oppermann, M.
Right arrow Articles by Castrop, H.

BASIC RESEARCH

Atrap Deficiency Increases Arterial Blood Pressure and Plasma Volume

Mona Oppermann*, Bernhard Gess{dagger}, Frank Schweda{dagger} and Hayo Castrop{dagger}

*Children's Hospital, University Medical Center, and
{dagger}Institute of Physiology, University of Regensburg, Regensburg, Germany

Correspondence: Dr. Hayo Castrop, Institute of Physiology, University of Regensburg, Universitätsstrasse 31, 93040 Regensburg, Germany. Phone: +49-941-943-2967; Fax: +49-941-943-4315; E-mail: hayo{at}castrop.com

Received for publication November 11, 2009. The angiotensin receptor-associated protein (Atrap) interacts with angiotensin II (AngII) type 1 (AT1) receptors and facilitates their internalization in vitro, but little is known about the function of Atrap in vivo. Here, we detected Atrap expression in several organs of wild-type mice; the highest expression was in the kidney where it localized to the proximal tubule, particularly the brush border. There was no Atrap expression in the renal vasculature or juxtaglomerular cells. We generated Atrap-deficient (Atrap–/–) mice, which were viable and seemed grossly normal. Mean systolic BP was significantly higher in Atrap–/– mice compared with wild-type mice. Dose-response relationships of arterial BP after acute AngII infusion were similar in both genotypes. Plasma volume was significantly higher and plasma renin concentration was markedly lower in Atrap–/– mice compared with wild-type mice. 125I-AngII binding showed enhanced surface expression of AT1 receptors in the renal cortex of Atrap–/– mice, accompanied by increased carboanhydrase-sensitive proximal tubular function. In summary, Atrap–/– mice have increased arterial pressure and plasma volume. Atrap seems to modulate volume status by acting as a negative regulator of AT1 receptors in the renal tubules.




This article has been cited by other articles:


Home page
HypertensionHome page
Z. Zhang and V. J. Dzau
Angiotensin II Type 1 Receptor-Associated Protein Is an Endogenous Inhibitor of Angiotensin II Type 1 Receptor Action in Cardiac Hypertrophy: Role in Check and Balance
Hypertension, May 1, 2010; 55(5): 1086 - 1087.
[Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP